Rallybio (NASDAQ:RLYB) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.37) by 29.73 percent. This is a 42.22 percent increase over losses of $(0.45) per share from the same period last year. The company reported $299.00 thousand in sales this quarter.